key: cord-0310742-koc6505h authors: Guirakhoo, Farshad; Wang, Shixia; Wang, Chang Yi; Kuo, Hui-Kai; Peng, Wen-Jiun; Liu, Hope; Wang, Lixia; Johnson, Marina; Hunt, Adam; Hu, Mei Mei; Monath, Thomas P.; Rumyantsev, Alexander; Goldblatt, David title: High neutralizing antibody levels against SARS-CoV-2 Omicron BA.1 and BA.2 after UB-612 vaccine booster date: 2022-05-09 journal: bioRxiv DOI: 10.1101/2022.03.18.484436 sha: 29aaaf76f9b234e9bea5a05e49ff3d8e1ea703a9 doc_id: 310742 cord_uid: koc6505h The highly transmissible Omicron variant has caused high rates of breakthrough infections among vaccinated and convalescent individuals. Here, we demonstrate that a booster dose of UB-612 vaccine candidate delivered 7-9 months after primary vaccination increases neutralizing antibody levels by 131-, 61- and 49-fold against ancestral SARS-CoV-2, Omicron BA.1 and BA.2 variants, respectively. Based on the RBD protein binding antibody responses, we estimated a ∼95% efficacy against symptomatic COVID-19 caused by the ancestral strain after a UB-612 booster. Our results support UB-612 vaccine as a potent booster against current and emerging SARS-CoV-2 variants. In November 2021, the Omicron (B.1.1.529) Variant of Concern (VOC) was first 53 reported in South Africa and quickly spread, becoming the dominant SARS-CoV-2 variant 54 worldwide. Omicron's high transmissibility and potential for immune system evasion, as 55 Two doses of UB-612 showed modest neutralizing activity against the authentic wild-108 type SARS-CoV-2 ancestral strain (Victoria/1/2020) (GMT VNT50 of 47.0), and very low 109 activity against Omicron's BA.1 and BA.2 sublineages (GMT VNT50 of 10-11) (Fig. 1B) (n=15) . 110 Similarly, a 2-dose immunization with mRNA vaccines has been shown to result in low levels of 111 Omicron neutralizing antibody responses: (i) mRNA-1273 on day 21 after immunization 112 stimulated a GMT pVNT50 of 14, and (ii) BNT162b2 on day 28 after immunization lead to a 113 GMT pVNT50 of 7 [6, 7] . 114 A booster dose of UB-612 delivered at 7-9 months after the primary series increased 115 neutralizing antibody titers against the ancestral strain, as well as Omicron BA.1 and BA.2 116 variants, to GMT VNT50 of 6,159, 670, and 485, respectively, which constitutes 131-, 61-, and 117 49-fold higher GMTs than those achieved after 2 doses (Fig. 1B) . The estimated decrease in 118 neutralization titers against Omicron BA.1 and BA.2 in 15 sera obtained 2 weeks after UB-612 119 booster, was 9.2-and 12.7-fold, respectively, compared with the ancestral Victoria strain. 120 Previously, only a 5.5-fold decrease against BA.1 was reported when 20 sera from UB-612 121 vaccinated participants were tested in a pseudovirus-based neutralization assay (GMT pVNT50 of 122 12,778 against the Wuhan strain, vs. 2,325 against the BA.1 strain) [9] . These data support the 123 breadth of UB-612−elicited neutralizing antibodies across multiple SARS-CoV-2 variants after 124 the booster, a differentiation property of UB-612 primarily attributed to its subunit protein RBD 125 antigenic component [10] . 126 7 We evaluated reactivity of UB-612−elicited antibodies to S and RBD proteins, using 15 129 sera from the Phase 1 trial (V123) participants and 84 randomly selected sera from Phase 2 trial 130 participants immunized with UB-612 (Tables S1-S2 ). These sera were tested in 2 ELISA-based 131 assays for IgG direct binding to recombinant S and RBD proteins, and inhibition of recombinant 132 S and RBD protein binding to the human angiotensin-converting enzyme 2 (hACE2) receptor. A 133 third dose of UB-612 booster immunization stimulated broadly reactive IgG antibodies, 134 effectively binding to RBDs of 14 divergent SARS-CoV-2 variants, including Alpha, Beta, 135 Gamma, Delta, and Omicron ( Fig. 1C and Fig. S1 ). participants by more than 16-and 13-fold, and increased antibody GMTs to 2,138 and 6,767 161 (BAU/mL), respectively, matching those achieved by 2 immunizations with the mRNA vaccines. 162 We further utilized a vaccine efficacy prediction model based on the RBD activity of IgG 163 antibodies to the ancestral strain, extending previous models based on neutralizing antibodies 164 [13] or S protein−binding activities [12] . According to this model, the predicted vaccine efficacy 165 of UB-612 against symptomatic disease caused by the prototype strain after 2 doses is ~72% 166 (235 BAU/mL) with sera from 15 Phase 1 participants, ~82% (494 BAU/mL) with sera from 84 167 randomly selected Phase 2 participants, and ~95% after the booster dose (6,767 BAU/mL), with 168 sera from 15 Phase 1 participants ( Fig. 2 and Fig. S4) . CT NTD RBD SD1 SD2 FP HR2 CD CH HR1 1 14 306 331 528 591 686 816 910 985 1035 1086 1163 1211 1273 19 24 25 26 27 67 Rapid epidemic expansion of the SARS-CoV-2 250 Omicron variant in southern Africa Is Omicron the last SARS-CoV-2 Variant of Concern? Scientific 257 rationale for developing potent RBD-based vaccines targeting COVID-19 Neutralizing antibodies against the SARS-260 CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 261 booster vaccination SARS-CoV-2 Omicron Variant Neutralization 263 after mRNA-1273 Booster Vaccination Neutralization of SARS-CoV-2 Omicron by 265 BNT162b2 mRNA vaccine-elicited human sera A Novel SARS-CoV-2 Multitope Protein/Peptide 267 Vaccine Candidate is Highly Immunogenic and Prevents Lung Infection in an AAV 268 hACE2 Mouse Model and non-human primates A multitope SARS-COV-2 vaccine provides long-271 lasting B cell and T cell immunity against Delta and Omicron variants Potent Anti-Delta Effect By a Booster Third-Dose of 274 UB-612, a Precision-Designed SARS-CoV-2 Multitope Protein-Peptide Research Square 275 Standard and Reference Panel for anti-SARS-CoV-2 antibody on behalf of the ISARIC4C Towards a population-based threshold of 284 protection for COVID-19 vaccines Neutralising antibody titres as predictors of 286 protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. The 287 SARS-CoV-2 mRNA boost Vaccine protection against the SARS-CoV-2 292 Omicron variant in macaques